Fovea Pharmaceuticals   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 4
Founded: Paris France (2005)
Status: Acquired by Sanofi-Aventis (2009)

Organization Overview

First Clinical Trial
2008
NCT00697944
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Fovea | Fovea Pharmaceuticals SA

Active Ingredients

Drugs in Phase 4 Trials (1)

amphotericin b (fungizone) (1 trial)

Drugs in Phase 2 Trials (4)

arsenic trioxide (trisenox) (1 trial)

cyclosporine (sandimmune) (2 trials)

prednisone (meticorten) (2 trials)

safotibant (1 trial)

Drugs in Phase 1 Trials (1)

ecallantide (Kalbitor) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Conjunctivitis (Phase 2)

Conjunctivitis, Allergic (Phase 2)

Diabetic Retinopathy (Phase 2)

Edema (Phase 2)

Graft vs Host Disease (Phase 2)

Immune System Diseases (Phase 2)

Inflammation (Phase 2)

Macular Edema (Phase 2)

Retinal Vein Occlusion (Phase 1)

Sepsis (Phase 4)

Toxemia (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 6
  • # of Trial APIs: 6